Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00225719
Status:
COMPLETED
Last Update Posted:
2008-11-10
First Post:
2005-09-23
Brief Title:
Effect of rHDL on Atherosclerosis - Safety and Efficacy THE ERASE TRIAL
Sponsor:
CSL Limited
Organization:
CSL Limited
Study Overview
Official Title:
Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound
Status:
COMPLETED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Currently available therapies to treat Acute Coronary SyndromesACS have several limitations including the relatively long treatment duration required before apparent significant benefit the inability to achieve reversal of the atherosclerotic process and poor patient compliance due to chronicity of therapy This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound IVUS in patients after acute coronary syndromes ACS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None